Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics Reports Interim Melanoma Data: 2 of 8 Partial Responses

Neutral Impact 3 of 5 other

Perspective Therapeutics (CATX) filed an 8-K on November 6, 2026 with a press release and poster presenting updated interim results from its Phase 1/2a trial of [212Pb]lapemelanotide zapixetar (VMT01) in unresectable or metastatic melanoma, presented at the SITC 41st Annual Meeting in Phoenix. The filing reports antitumor activity at the 3.0 mCi dose and no dose-limiting toxicities across 20 patients, but the sample is small and the company says it is still evaluating dose optimization. The update is early-stage clinical data and contains no financial results or guidance.

Key points

  • Data cover 20 patients in three monotherapy cohorts as of the September 18, 2026 data cutoff; no dose-limiting toxicities were reported
  • At the 3.0 mCi dose, 2 of 8 patients had objective partial responses and the disease control rate was 75%
  • Grade 3 or higher treatment-emergent adverse events occurred in 5 of 20 patients (25%), none considered treatment-related

The filing

CompanyPerspective Therapeutics, Inc. (CATX)
Form8-K, current report
Filed with the SECNov 6, 2026, 12:05 PM ET
Accession number0001193125-26-451227

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.